Stay aware of the latest advances from the academic thought leaders and expert clinicians of the Department of Psychiatry at Mount Sinai. Led by René Kahn, MD, PhD, our team is at the forefront of unlocking the complex interactions between biological processes and the myriad states of the human mind. Ranked No. 6 among the nation's psychiatry departments for National Institute of Health funding, Mount Sinai is unrelenting in its commitment to advancing life-changing treatment. The Department is a vibrant community of psychiatric clinicians, researchers, educators, and trainees, and is a national model for groundbreaking clinical research in neuropsychiatry. Our programs offer a wide range of diagnostic and treatment services for conditions ranging from addiction, to major depression, autism, and schizophrenia.
Stay aware of the latest advances from the academic thought leaders and expert clinicians of the Department of Psychiatry at Mount Sinai. Led by René Kahn, MD, PhD, our team is at the forefront of unlocking the complex interactions between biological processes and the myriad states of the human mind. Ranked No. 6 among the nation's psychiatry departments for National Institute of Health funding, Mount Sinai is unrelenting in its commitment to advancing life-changing treatment. The Department is a vibrant community of psychiatric clinicians, researchers, educators, and trainees, and is a national model for groundbreaking clinical research in neuropsychiatry. Our programs offer a wide range of diagnostic and treatment services for conditions ranging from addiction, to major depression, autism, and schizophrenia.
In June, Mount Sinai launched a comprehensive, state-of-the-art destination for integrated mental health, substance use, and primary care, with a commitment to fostering breakthrough clinical research: the Mount Sinai-Behavioral Health Center.
A leader of neuroimaging and addiction science at Mount Sinai has discovered the impairment of a brain circuit pathway as a key driver in human drug addiction, extending previous findings in animal models. These findings hold potential ...
Scientists at the Icahn School of Medicine at Mount Sinai have developed a lipid nanoparticle system capable of delivering messenger RNA (mRNA) to the brain via intravenous injection, a challenge that has long been limited by the protective ...
The Department of Psychiatry at Mount Sinai continues its upward trend of changing the behavioral health care landscape through innovative research and outstanding clinical care. In 2024, we’ve seen our centers expand, new locations open, ...
A Mount Sinai researcher has spent years uncovering the impact of cannabis on neurodevelopment, especially among those at high risk of substance-use disorder. Now, amid a landscape of increasingly potent cannabis market entering the market ...
The recent expansion of Mount Sinai’s psychedelic research center marks a significant step forward in advancing clinical trials and training clinicians in groundbreaking treatments for mental health conditions.
Research from Mount Sinai provides evidence for the first time that subjective beliefs can affect neural activity. In an imaging study, the team found a dose-dependent relationship between beliefs about nicotine and corresponding thalamus ...
The Psychiatry Residency Program at the Icahn School of Medicine at Mount Sinai has an exciting new venture: the incorporation of the Mount Sinai-Behavioral Health Center (MSBHC) as a major clinical teaching site. Residents will get the ...
A large cohort study from Mount Sinai provides evidence, for the first time, on familial risk of postpartum psychosis. The findings pave the way for preventive work that can be done for women at increased risk.
Researchers at the Icahn School of Medicine at Mount Sinai have developed an innovative approach—demonstrated in mouse models and isolated human brain tissue—to safely and effectively deliver therapeutics into the brain, providing new ...
Mount Sinai researchers have discovered for the first time a neural mechanism for memory integration that stretches across both time and personal experience.
A collaborative study between researchers at the Icahn School of Medicine at Mount Sinai and Harvard Medical School has identified genetic mutations that occur during brain development and may contribute to the development of schizophrenia.
Mount Sinai Health System and IBM Research today announced the launch of the Phenotypes Reimagined to Define Clinical Treatment and Outcome Research (PREDiCTOR) study.
A blood biomarker study focusing on Asian populations will provide better ways to detect, diagnose, and treat Alzheimer’s disease in a group that has been underrepresented in research of the neurodegenerative disease.
With treatments for neuropsychiatric illnesses, such as schizophrenia, having remained the same for decades, a research consortium is changing the field with new studies, backed by new approaches and tools. Two studies from Mount Sinai ...
Researchers from the Icahn School of Medicine at Mount Sinai have shed valuable light on the nuanced functions and intricate regulatory methods of RNA editing, a critical mechanism underlying brain development and disease.
"The Genesis of Schizophrenia: An Origin Story” by Mount Sinai researcher Rebecca Birnbaum, MD, and Daniel Weinberger, MD, Director and CEO of the Lieber Institute for Brain Development (LIBD) on the Johns Hopkins medical campus, is featured ...
Working under the umbrella of the PsychENCODE Consortium, the mental health research project established in 2015 by the National Institutes of Health, a team of Mount Sinai scientists has uncovered important new insights into the molecular ...
In line with their previous work, researchers from the Icahn School of Medicine at Mount Sinai showed that individuals with heroin use disorder have lower activity in the anterior and dorsolateral PFC when performing an inhibitory control ...
Mount Sinai researchers, in collaboration with scientists at The Rockefeller University, have uncovered a mechanism in the brain that allows cocaine and morphine to take over natural reward processing systems. Published online in Science ...
The Mount Sinai Department of Psychiatry is dedicated to improving the mental and emotional health in the communities we serve throughout New York and beyond.
A global network of institutions is working to uncover biomarkers that could help enlighten early-stage risks for developing psychosis. Now, this network is ready to begin testing novel interventions, with Mount Sinai primed to play a key role.
From its inception, the Seaver Autism Center for Research and Treatment at the Icahn School of Medicine at Mount Sinai has been leading the way in autism spectrum disorder research with its focus on genetics. In 2023, the Center celebrated ...
Mount Sinai’s Psychiatry Residency Program was created with the understanding that trainees need to be trained for the clinic and in the lab. After years of investments into resources for collaborative training, it has seen outstanding ...
Mount Sinai researchers have shown for the first time that a person’s beliefs related to drugs can influence their own brain activity and behavioral responses in a way comparable to the dose-dependent effects of pharmacology.
Targeting the disgust of food, rather than fear, in anorexia, a new study could change the treatment paradigm. Additionally, the study's team is ensuring that the trial is as inclusive as possible to help more youths by broadening the study inclusion criteria.
A team of researchers from the Icahn School of Medicine at Mount Sinai and Yale University School of Medicine has created the first “multiome” atlas of brain cell development in the human cerebral cortex across six broad developmental ...
The Icahn School of Medicine at Mount Sinai is one of 16 academic medical research centers to participate in the Asian Cohort for Alzheimer’s Disease (ACAD) study.
Dr. Qasim’s essay peers honestly into the thought process of a scientist performing intracranial research, watching human brain activity as it is recorded directly from the amygdala, the frontal cortex, and the hippocampus.
A new study assessed whether ChatGPT could reliably produce accurate references to supplement the literature search process. Out of thirty-five citations, ChatGPT only produced two that were accurate.
A genome-wide analysis of a model-derived binge-eating disorder (BED) phenotype 17 identifies risk loci and implicates iron metabolism. In this study, Mount Sinai researchers identify potential therapeutics implications for BED.
Babies are more likely to be born prematurely when either their father or mother has had a psychiatric diagnosis, according to a study conducted by researchers at the Icahn School of Medicine at Mount Sinai and the Karolinska Institute
Men were significantly more vulnerable than women to overdose deaths involving opioid and stimulant drugs in 2020-2021, according to a new study analyzing data from across the United States.
A grant from the New York State Office of Mental Health will help patients at Mount Sinai’s Cohen Center for Pediatric Comprehensive Care (CCPCC), which serves more than 10,000 families, gain access to HealthySteps, a national evidence-based ...
This study is the first to examine in utero exposure to stimulants and long term child outcomes. Researchers examined almost 900 children who were exposed to ADHD during the mothers’ pregnancy and 1270 children who were not.
Researchers have identified two previously unknown genes linked to schizophrenia and newly implicated a third gene as carrying risk for both schizophrenia and autism.
The year 2022 was a productive and prolific one for our department. We launched the Center for Disease Neurogenomics—one of the few in the world with access to brain tissue and population-level datasets.
The Jeff and Lisa Blau Adolescent Consultation Center for Resilience and Treatment is studying 10 rare genetic mutations that are implicated in schizophrenia.
Yasmin Hurd, PhD, and Helen Mayberg, MD, have paved new paths in addiction and depression research by opening new lines of inquiry into treatment approaches: the therapeutic potential of CBD, and a specific target for deep brain stimulation.
While people who are pregnant can easily learn how to safeguard their physical health and that of their babies, information about mental health concerns is scarcer.
Rachel Yehuda, PhD, is exploring whether psychedelics can be a useful treatment for post-traumatic stress disorder (PTSD). Her journey began with a study on 3,4-methylenedioxy-methamphetamine (MDMA) in veterans and is expanding to investigate psilocybin.
Past social trauma is encoded by a population of stress/threat-responsive brain cells that become hyperactivated during subsequent interaction with non-threatening social targets.
Stem cell-derived neurons from combat veterans with post-traumatic stress disorder (PTSD) react differently to a stress hormone than those from veterans without PTSD.
Researchers from the Icahn School of Medicine at Mount Sinai have learned that the way the brain processes the complex emotion of regret may be linked to an individual’s ability to cope with stress, and altered in psychiatric disorders like depression.
White matter in the brain that was previously implicated in animal studies has now been suggested to be specifically impaired in the brains of people with addiction to cocaine or heroin.
New data from the longitudinal Stress in Pregnancy Study have identified earlier onset and higher rates of developmental psychopathology among children whose mothers were pregnant during Superstorm Sandy.
Mount Sinai’s Psychosis Risk Program provides patients and families with education and CBT early on, as well as the opportunity to participate in research trials
Each day, approximately 17 veterans die by suicide, according to the 2020 National Veteran Suicide Prevention Annual Report. Of those lives lost, 68% die from a self-inflicted firearm injury.
At the Aspen Ideas Festival, a distinguished panel of researchers and entrepreneurs, including Mount Sinai’s Rachel Yehuda, PhD, discuss pioneering approaches to psychedelics for mental health care
In the East Harlem neighborhood of New York City, residents without access to health insurance are receiving free outpatient mental health care, thanks to an innovative project at the Icahn School of Medicine at Mount Sinai.
Dr. Khachadourian is helping to paint a more complete picture of the environmental exposures that affect pregnant people and their developing children.
In 2021, two professors from the Department of Psychiatry received Mount Sinai's highest honors in academic medicine: Rita Goldstein, PhD, and Rachel Yehuda, PhD.
For the first time, stem cell-derived organoid models are allowing scientists to study the cellular development and intercellular interactions among microglia and other cell types within a 3D human brain microenvironment.
Mount Sinai's Center for Stress, Resilience and Personal Growth was created to help frontline health workers cope with the psychosocial trauma of the COVID-19 pandemic.
Mount Sinai's Department of Psychiatry provides residents and fellows with the resources and support they need to turn patient experience into valuable research so they can become fluent in both science and medicine.
The Department of Psychiatry is training students, residents, and fellows on the issues of social justice and diversity and working toward the elimination of race-based discrepancies in the diagnosis and treatment of patients.
The unique pairing of the Nash Family Center for Advanced Circuit Therapeutics and the Center for Computational Psychiatry is generating some of the nation's most advanced research into the brain.
An estimated three-quarters of all psychiatric disorders debut prior to or during adolescence. To address this, in October 2021, Mount Sinai established the Jeff and Lisa Blau Adolescent Consultation Center for Resilience and Treatment.
In addition to launching three centers, we were ranked No. 7 in National Institutes of Health (NIH) funding for psychiatry, published more than 850 papers, completed more than 800,000 outpatient visits, and received $49 million in active grants.
Tyree Grant, LCSW, presents a case of a 70 year old patient with anxiety and depression. Michael Katz, PhD, then gives a didactic presentation on screening for depression, including common screening tools, questions to ask, and more.
Dr. Emily Gutowski presents a case of a patient with a history of severe depression refractory to many lines of treatment. Dr. Michael Katz presents on psychotherapeutic interventions for depression management.
Dr. Stephen Sisselman presents a case of a young adult with depression and suicidal thoughts, as well as cultural and family barriers to patient support. Dr. Katie Angelova speaks about pharmacological management of depression in the primary care setting.
Dr. Bruce Chung presents a case regarding an adult woman with a history of depression and anxiety. Dr. Vanessa Litoff then gives a didactic presentation on barriers to screening for anxiety, focusing especially on OCD and panic disorder.
Dr. Carol Wurzel shares the case of a 13-year-old patient with symptoms of anxiety and depression for whom she is seeking a differential diagnosis and diagnostic clarification. Dr. Vanessa Litoff then presents on psychotherapy for anxiety management.
Dr. Jill Sisselman shares a case of a geriatric patient with high anxiety and posed the question of benodiazepines versus an SSRI in this patient. Dr. Mary Kate Christopher presents on pharmacological management of anxiety in primary care.
Dr. Nikita Barai presents a case of a geriatric patient presenting with anxiety and depression and multiple ED visits. Drs. Seema Quraishi and Jordan Schwartzberg present on managing side effects of commonly prescribed anxiolytics.
